ID
KERX

Integral Derivatives’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Integral Derivatives’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-11,627
Closed -$54K – 1165
2017
Q4 		$54K Buy
+11,627
New +$64.1K ﹤0.01% 1067

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Integral Derivatives's KERX Position: Q1 2018 in Review

Integral Derivatives sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2018, closing a stake of 11,627 shares — an estimated $54K sold.

Integral Derivatives first reported a position in KERX in Q4 2017 and held it in 1 quarter. The position peaked at $54K in Q4 2017. 125 funds tracked by Wall St. Rank hold KERX as of Q1 2018.

  • Integral Derivatives reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2018 after selling out during the quarter.
  • Integral Derivatives sold 11,627 Keryx Biopharmaceuticals Inc shares in Q1 2018, an estimated $54K.
  • Integral Derivatives first reported a position in Keryx Biopharmaceuticals Inc in Q4 2017 and held it in 1 quarter.
  • Integral Derivatives's Keryx Biopharmaceuticals Inc position peaked at $54K in Q4 2017.
  • 125 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2018.

Based on Integral Derivatives's 13F filing for Q1 2018, filed 19 Apr 2018.